SCHEMBL14897564

SCHEMBL14897564

O=C(Nc1cccnc1)c1ccnc2cc(-c3ccccc3C(F)(F)F)nn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SGMS2 Q8NHU3 1/20 0.46
▸ NOTUM Q6P988 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ BRAF P15056 6/20 0.45
▸ ATR Q13535 1/20 0.44
▸ NAMPT P43490 4/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TRPV1 Q8NER1 1/20 0.43
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ EPHX2 P34913 2/20 0.41
▸ CHRM4 P08173 1/20 0.41
▸ CCNE2 O96020 1/20 0.41
▸ CCNE1 P24864 1/20 0.41
▸ CDK2 P24941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897487 0.89 BRAF (0.49) LMNABRAFATRALDH1A1TRPV1
SCHEMBL14897579 0.86 TSHR (0.45) HSD17B10BRAFATRSMN1; SMN2CYP1A2
SCHEMBL14897541 0.85 SGMS2 (0.46) SGMS2NOTUMLMNAHSD17B10ATR
SCHEMBL14897730 0.85 KMO (0.42) LMNABRAFATRALDH1A1CYP1A2
SCHEMBL14881572 0.83 TRPV1 (0.42) BRAFSMN1; SMN2TRPV1CYP1A2CHRM4
SCHEMBL14897488 0.83 CHRNB2 (0.45) HSD17B10BRAFCYP1A2CYP3A4CYP2D6
SCHEMBL14896941 0.82 SGMS2 (0.44) SGMS2NOTUMLMNAHSD17B10BRAF
SCHEMBL14897655 0.82 BRAF (0.60) BRAFCHRM4
SCHEMBL14897582 0.81 MAP3K5 (0.45) LMNABRAFALDH1A1SMN1; SMN2EPHX2
SCHEMBL14897864 0.81 HPGD (0.48) LMNAALDH1A1SMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288052-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-09-25 — — US disclosed
US-20140288052-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-09-25 — — US disclosed
WO-2013059594-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288052-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 SGMS2 4042/4885NOTUM 3955/4885LMNA 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback